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During this half a century since immunoglobulin A (IgA) nephropathy was firstly reported in 1968, several clinical and histo-
logical grading systems to predict the prognosis have been reported. In Japan, since the first version of clinical guideline for
IgA nephropathy was established in 1995, it was revised in 2014 to the third version which was the grading system based on
both clinical and histological risk factors. In this report, we have shown the details and evaluation of clinical grading system
of that Japanese guideline, and also shown the previous reported clinical grading system.
This report is secondary publication of previous our review report “Nippon Rinsho 77: 643-650, 2019”.
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Introduction
Immunoglobulin A (IgA) nephropathy as a disease entity
was first reported by Berger et al. in France 50 years ago,
in 1968.
１
While it was initially considered as a disease
with a good prognosis, it came to be recognized in the
1990’s that it, in fact, has a poor long-term prognosis,
with 30% of IgA nephropathy progress to end-stage renal
disease (ESRD) within 20 years from its onset.
２，３
Various
treatment strategies for IgA nephropathy have been re-
ported for avoiding ESRD, including treatment with ster-
oids and/or renin-angiotensin system (RAS) inhibitors
and tonsillectomy. In addition, attempts to identify the
risk factors for ESRD from among various clinicopa-
thological variables have been made, which have led to
the proposal that the disease be classified in accordance
with the clinical/pathological severity, based on such risk
factors.
In Japan, such classification is now included in the
guidelines for the management of IgA nephropathy in
clinical practice. In this paper, we review and discuss the
validity of clinical severity classification of this disease
adopted in the current IgA nephropathy management
guideline (3rd edition),
４
and also outline other reports
published until date concerning the classification of the
severity of IgA nephropathy on the basis of the labora-
tory test data.
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Table　1a　Prognostic criteria for IgA nephropathy.
Classification
Patients with IgA nephropathy are clinically divided into the following four groups at the 
time of renal biopsy. It should be noted, however,that the prognostic group as determined at 
the time of renal biopsy may change during the clinical course of the disease.
1 Good prognosis group Dialysis will probably never be required.
2 Relatively good prognosis group The likelihood of dialysis is relatively low.
3 Relatively poor prognosis group Dialysis is likely to be required within 5-20 years.
4 Poor prognosis group The possibility of dialysis within 5 years is high.
The purpose is to define prognostic criteria to aid the selection of an appropriate treatment in 
individual patients with IgA nephropathy. 
Adapted from reference 6 Jpn J Nephrol 2002.
Table　1b　Clinical parameters uses as prognostic criteria in addition to renal biopsy findings.
Parameters Relatively poor prognosis group Poor prognosis group
Blood pressure* (mmHg) 140-160/85-95 (persistent) >160/95 (persistent) 
Serum creatinine* (mg/dL) 1.3-1.5 ≥1.6
Creatinine clearance (mL/min) 50-80 <50
Urinary protein (g/day) 0.5-2.0 (persistent) ≥2.0 (persistent) 
Values for blood pressure and serum creatinine are different in children. 
Adapted from reference 6 Jpn J Nephrol 2002.
Clinical Severity Classification of IgA
Nephropathy in Japan
1．Changes in the clinical severity classifications in
management guidelines
Many of the severity grading systems proposed until
date from Japan, Asia, Europe and the USA are based on
the pathological findings, or a combination of the clinical
and pathological findings. There is hardly any severity
classification based solely on the laboratory test data.
This is probably because not only the clinical features,
but also the pathological features of this condition are di-
verse and very important in determining the severity
level of IgA nephropathy. In Japan, the first edition of
the IgA nephropathy management guideline was pub-
lished in 1995 by the Progressive Nephropathy Research
Group within the framework of the Ministry of Health
and Welfare Specific Disease Research Program.
５
Later,
in 2002, the 2nd edition of the same guideline was pub-
lished.
６
The revision at that time only consisted of addi-
tion of several sentences to the 1st edition (partial revi-
sion on the basis of new evidence collected after publica-
tion of the 1st edition). In this edition (2nd edition) of the
management guideline, “diagnostic criteria for IgA neph-
ropathy,” “criteria for predicting the prognosis of IgA
nephropathy,” and “guidelines for the treatment of IgA
nephropathy” were proposed. Of these, the “criteria for
predicting the prognosis of IgA nephropathy” represents
the so-called severity classification, according to which
patients with IgA nephropathy were divided into four
groups: the good prognosis group, relatively good prog-
nosis group, relatively poor prognosis group, and poor
prognosis group ( Table 1 a ) . This classification was
based on the glomerular findings and other histopa-
thological findings related to the renal tubules, intersti-
tium and vessels. Clinical findings were used only as ref-
erence criteria, “serving as an auxiliary means for pre-
dicting the prognosis in cases showing a tendency to-
wards aggravation of the blood pressure, serum cre-
atinine level, creatinine clearance and urinary protein ex-
cretion level” (Table 1b). Thus, the tendency towards a
lower significance attached to clinical findings relative to
the histopathological findings in the 1st edition of the
guideline continued into the 2nd edition.
Publication of the 3rd edition (2011) , however, in-
volved a full-scale revision of the guideline.
４
This latest
revision was based on the recognition that the clinical
findings had been given less importance in the previous
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two editions and that underestimation of the importance
of clinical findings may be problematic, as in clinical
practice, there may be cases showing discrepancies be-
tween the pathological findings and clinical findings (for
example, it is unknown to what extent importance should
be attached to clinical findings in cases with a high uri-
nary protein excretion level despite only mild histopa-
thological changes of the renal tissue). As a result, estab-
lishment of a classification giving equal weightage to the
clinical and histopathological findings was proposed. We
believe that this latest classification is more reliable, es-
pecially in view of the fact that the clinical findings of
IgA nephropathy at presentation are diverse (e.g., prote-
inuria, hematuria, renal function impairment).
2．IgA nephropathy management guideline ―3rd
edition―
The 3rd edition of the IgA nephropathy management
guideline was prepared on the basis of the results of lo-
gistic regression analysis performed to determine the re-
lationship between the histopathological/laboratory find-
ings and the renal prognosis in a total of 287 cases se-
lected from 16 facilities nationwide between February
1980 and January 2002. The selected patients included:
(1) patients from whom 10 or more glomeruli could be
collected by renal biopsy; (2) patients who could be fol-
lowed up for 5 years or more after renal biopsy or pa-
tients who had begun to receive dialysis ; (3) patients
whose treatment details were well known (regardless of
the nature of treatment). The detailed data used for prepa-
ration of the 3rd edition have also been reported by Ok-
onogi et al.
７
After the exclusion of 17 cases with incomplete data,
analysis of the remaining 270 patients revealed that 48 of
the 270 patients progressed to ESRD. Two-group com-
parison between ESRD group and renal survival group
and univariate analysis identified high urinary protein ex-
cretion, low estimated glomerular filtration rate (eGFR),
high serum uric acid level, advanced age, male gender
and presence of hypertension as factors significantly as-
sociated with ESRD. However, there was no influence of
hematuria (which was prevalent at equivalent rates in the
two groups) , whose importance has been increasingly
recognized in recent years. The multivariate logistic re-
gression analysis, performed using the above mentioned
risk factors identified as significant by the univariate
analysis plus several additional factors, including hema-
turia, history of steroid therapy (significance found in
univariate analysis), history of treatment with RAS in-
hibitors (no significance found), revealed that each 1 g/
day increase of the urinary protein excretion resulted in a
1.61-fold elevation of the risk (odds ratio) for initiation
of dialysis (95% confidence interval (CI) 1.20-2.17; p =
0.002), and each 10 mL/min/1.73 m
2
increase of the
eGFR resulted in a 0.64-fold decrease of the odds ratio
for the initiation of dialysis (95% CI 0.49-0.84; p = 0.01);
thus, these two parameters were identified as factors sig-
nificantly associated with ESRD. However, hypertension,
which had been included as one of the reference factors
in the 2nd edition was not adopted as a criterion in the
laboratory test data-based severity classification in the
3rd edition of the guideline, because it was found to
show no association with the prognosis (odds ratio 1.28,
95% CI 0.45-3.66; p = 0.646). Furthermore, according to
the receiver operating characteristic (ROC) analysis, the
areas under curve (AUCs) of the ROC curve for protein-
uria and eGFR were reported to be 0.774 and 0.777, re-
spectively. In addition, on the basis of an earlier report by
Okonogi et al.,
８
urinary protein excretion 0.5 g/day and
eGFR 60 mL/min/1.73 m
2
were set as the cutoff levels
through application of these parameters to the cutoff de-
termining equation, namely, threshold score (−1.86) =
0.722 + 0.364 × urinary protein − 0.046 × eGFR. The
patients could be divided into four classes of disease se-
verity based on these parameters: Class I (urinary protein
excretion <0.5 g/day and eGFR 60 mL/min/1.73 m2),
Class II (urinary protein excretion <0.5 g/day and eGFR
>60 mL/min/1.73 m
2
), Class III (urinary protein excretion
0.5 g/day and eGFR60 mL/min/1.73 m2), and Class IV
(urinary protein excretion0.5 g/day and eGFR >60 mL/
min/1.73 m
2
). Because only 7 cases were included in
Class II, and there were no cases of renal death, Class II
was combined with Class I to form a new class (C-Grade
I). Thus, the 4-category classification was changed to a
3-category classification (C-Grades I, II and III, Table 2,
left). When this classification was applied, rather reason-
able results were obtained, with the odds ratio for renal
death in the C-Grade II group being 6.4-fold higher, and
that in the C-Grade III group being 42.5-fold higher than
the ratio in the C-Grade I group (95% CI 1.4-28.4; p =
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Odds ratio 95% CI p-value
C-Grade I <0.5 - 1 − −
C-Grade II 0.5≤ 60≤ 6.4 1.4-28.4 0.015
C-Grade III <60 42.5 9.6-189 <0.001
CI, confidence interval.
Based on reference 4 Jpn J Nephrol 2011 and reference 7 Clin Exp Nephrol 2019.




H-Grade I H-Grade II H-Grade III+IV
C-Grade I 1/72 (1.4%) OR: 1 0/10 (0%) OR: 0 1/5 (20%) OR: 17.8
C-Grade II 7/64 (11%) OR: 8.7 6/41 (15%) OR: 12.2 3/18 (17%) OR: 14.2
C-Grade III 2/5 (40%) OR: 47.3 6/21 (29%) OR: 28.4 22/34 (65%) OR: 130
The number of patients progressed to ESRD/total number of patients (%).
OR, odds ratio vs. H-Grade I/C-Grade I.
Adapted from reference 4 Jpn J Nephrol 2011.
0.015, and 9.6-189, p < 0.001) (Table 2, right). This re-
sult has been explained as an outcome of addition of the
histological severity (H-Grade) to the classification in the
3rd edition of the IgA nephropathy management guide-
line (Table 3). Also, in the aforementioned study by Ok-
onogi et al.,
８
who reported the equation for calculating
the cutoff levels of urinary protein excretion and eGFR
for the 3rd edition (urinary protein excretion 0.5 g/day
and eGFR 60 mL/min/1.73 m
2
), the authors analyzed the
data of 116 patients who had been followed up for a
maximum of 25 years, adopting the renal biopsy-based
glomerulus count and the minimum follow-up period,
similar to the entry criteria for the 3rd edition; the uni-
variate analysis identified only urinary protein excretion
and eGFR as the risk factors for renal death among all
the clinical variables analyzed (urinary protein excretion,
eGFR, serum uric acid, age, gender, presence/absence of
hypertension and hematuria) . Also, in the multivariate
analysis performed using these clinical variables plus the
history of steroid therapy and history of treatment with
RAS inhibitors, only urinary protein excretion and eGFR
were identified as significant risk factors for renal death.
The same investigators additionally reported that in the
ROC curve analysis, the AUC for urinary protein excre-
tion was 0.752 and that for eGFR was 0.799, and that the
combination of the two factors was more useful for pre-
diction of the prognosis (AUC: 0.815). Furthermore, they
performed a two-graph ROC (TG-ROC) analysis and set
the threshold score (sensitivity approximately equal to
specificity) at −1.86, followed by calculation of the cut-
off values using the aforementioned equation. They re-
ported cutoff levels of 1.0 g/day for urinary protein ex-
cretion and 64 mL/min/1.73 m
2
for the eGFR, and classi-
fied the severity of the disease in the patients according
to the laboratory abnormalities as follows: Grade I: uri-
nary protein excretion <1.0 g/day and eGFR 64 mL/
min/1.73 m
2
; Grade II: urinary protein excretion <1.0 g/
day and eGFR <64 mL/min/1.73 m
2
; Grade III: urinary
protein excretion1.0 g/day and eGFR64 mL/min/1.73
m
2
and Grade IV: urinary protein excretion 1.0 g/day
and eGFR <64 mL/min/1.73 m
2
. However, similar to the
case in the cohort examined for preparing the 3rd edition
of the guideline, the number of Grade II patients was
small (12 cases) and there were no cases of renal death in
this group. For this reason, Grade II was combined with
Grade I for the evaluation. In this latter evaluation, addi-
tionally adopting the effects of steroid therapy and treat-
ment with RAS inhibitors, the odds ratio for renal death
in the Grade III patients cases was 9.6-fold (95% CI 1.0-
89.4; p = 0.048), and that in the Grade IV patients was
43.9-fold (95% CI 4.7-407, p = 0.001), as compared to
that in the Grade I + II patients. Thus, despite some dif-
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ferences in the data recorded, this evaluation also demon-
strated the validity of the laboratory test data-based se-
verity classification established using urinary protein ex-
cretion and eGFR.
Other Severity Classifications Based
on Laboratory Data
Many papers have been published concerning various
risk factors for the progression of IgA nephropathy, but
few have summarized these factors into a scoring system
and reported the validity of such a scoring system for de-
termining the disease severity. As mentioned above, the
reports often took into account the histological severity,
and according to our literature search, only the reports by
Magistroni et al.
９
and Xie et al.
１０
have adopted solely the
laboratory test data-based severity classification, other
than our report. This section will focus on these reports
and pay attention only to the laboratory test data-based
severity classification among the classification systems
based on the clinicopathological severity.
Magistroni et al. conducted a multivariate analysis of
237 Caucasians with IgA nephropathy in Italy, and iden-
tified four factors (Cr at renal biopsy, urinary protein ex-
cretion, age and gender) as being risk factors for ESRD,
and proposed a clinical prognostic index (CPI). Because
Cr is most closely associated with ESRD, this CPI as-
signs a score 2 for Cr >1.4 mg/dL, 1 to urinary protein
excretion >1.0 g/day, 1 to the presence of hypertension,
and 1 to age >30 years (total score 5). They divided the
patients into a low CPI group (CPI score 2) and high
CPI group (score3), reporting that the 10-year survival
rate was significantly higher in the low CPI group
(91.7%) than in the high CPI group (31.1%) (p < 0.001).
They conducted evaluation of its validity in another dis-
trict of Italy, in 73 Caucasians, and reported that the 10-
year survival duration was significantly higher in the low
CPI group (80.5%) than in the high CPI group (31.1%)
(p = 0.007).
Xie et al. in China conducted multivariate analysis us-
ing a stepwise Cox proportional hazards model in 619
patients with IgA nephropathy, which identified four fac-
tors, i.e., eGFR, hemoglobin (Hb), serum albumin (Alb)
and systolic blood pressure at the time of renal biopsy as
factors associated with the prognosis. They divided the
Risk Score (RS) calculated as 6.932 − 0.039 × eGFR
(mL/min/1.73 m
2
) − 0.23 × Hb (g/dL) − 0.762 × Alb
(g/dL) + 0.016× systolic blood pressure (SBP, mmHg)
into three tertiles: 1st tertile: RS <−0.89, 2nd tertile: −
0.89-0.99, and 3rd tertile: >0.99. When the odds ratio for
ESRD in the 1st tertile was deemed to be 1, the ratio was
15.3 in the 2nd tertile (95% CI 2.0-115.0) and 79.8 in the
3rd tertile (95% CI: 11.0-580.3), demonstrating that the
risk for ESRD increased as the RS increased. It is note-
worthy that in the study conducted by Xie et al., urinary
protein excretion, which is generally known as a power-
ful prognostic factor, was not identified as a factor asso-
ciated with ESRD, because of the presence of Alb, which
was correlated inversely with renal death according to the
multivariate analysis, and of Hb, which was found as a
risk factor associated with IgA nephropathy ( lower in
IgA nephropathy patients than in healthy individuals and
the risk of disease progression rising by 20% with each
1.0 g/dL reduction of the Hb). The AUC of the ROC
curve in their study was higher than that reported by Ber-
thoux et al., or later by Goto et al., even though Xie et al.
emphasized that these data could be derived from routine
laboratory tests and that their results were from a large-
scale cohort study involving more than 600 subjects.
However, it seems necessary to evaluate its validity in
other ethnic groups, etc.
In the severity classification proposed by Berthoux et
al.,
１１
which additionally took into account the histological
findings, the absolute renal risk (ARR) was calculated by
simply assigning a score of 1 to each of (1) hypertension
(140/90 mm Hg), (2) urinary protein excretion (1 g/day
or more), and (3) seriousness level of tissue damage, to
yield a total score being 3. They reported the incidence of
events (ESRD or mortality) in 332 Caucasian patients
with IgA nephropathy in France whose data were ana-
lyzed prospectively. The incidence of events at 10 years
and 20 years was 2% and 4% in the AAR0 (ultralow risk)
group, 2% and 9% in the AAR1 (high-risk) group, 7%
and 18 % in AAR2, and 29% and 64% in the AAR3 (ul-
trahigh risk) group, respectively. The odds ratio analyzed
by the COX proportional hazard model, with AAR3 serv-
ing as the control group, was 0.28 (95% CI 0.14-0.60; p
< 0.0009) in the AAR2 group, 0.09 (95% CI 0.03-0.30, p
< 0.0001) in the AAR1 group, and 0.06 (95% CI 0.02-
0.17; p < 0.0001) in the AAR0 group, indicating a reduc-
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Table　4　(a) Scores to estimate the risk of ESRD by demographic and clinical factors (b) The estimated 10-year 
risk of ESRD by total score (c) Scores of Norwegian cohort.
(a) Scores to estiate the risk of ESRD
Factors Score
Gender Male 6
Age <30 years 12









Hematuria 1-29 RBC/HPF 8
Serum albumin <4.0 g/dL 7







H-Grade Grade III or IV 5
(b) estimated 10-year risk of ESRD 
by total score
(c) Grading of Norwe-
gian cohort










Based on reference 13 Nephrol Dial Transplant 2009 and refer-
ence 14 Nephrol Dial Transplant 2011.
tion in the incidence of events as the score decreased.
Wakai et al. in Japan prospectively followed 2,269 pa-
tients with IgA nephropathy from 97 facilities in Japan
for 7 years from 1995 to 2002 and analyzed the risk fac-
tors for disease progression.
１２
They scored the risk for re-
nal death at 4 years or 7 years using the laboratory test
data-based severity classification (gender, age, systolic
blood pressure, urinary protein excretion, hematuria, se-
rum total protein and Cr) and the histological severity
classification (Japanese IgA Nephropathy Management
Guidelines, 2 nd edition ) , and divided the scores into
many ranges (from −8 to 116) . High scores were as-
signed to elevation of the serum Cr and urinary protein
excretion, which had been found to be strong risk factors
in the multivariate analysis (Cr: score 0 for values 1.25
mg/dL and 47 for values 2.5 mg/dL; proteinuria: score
24 for qualitative assay 3+), while only one-digit lower
scores were assigned to gender, age, etc., which had been
identified as significant factors only in the univariate
analysis. The highest score assigned to the histopa-
thological severity was as low as 9. Thus, their scoring
system attached importance to the laboratory test data-
based severity classification.
Goto et al. reported a clinicopathological severity clas-
sification using data from the same cohort after extending
the follow-up period to 10 years, adopting a simpler scor-
ing system (Table 4a, b).１３ Unlike the previous classifi-
cation in which Cr was divided into 47 ranges, the GFR
was adopted, values of which were divided into 5 ranges
(identical to the number of chronic kidney disease [CKD]
stages). At the same time, Alb was adopted instead of
serum total protein ( which had been divided into 8
ranges), with only 2 ranges (< 4 g/dL or 4 g/dL). The
other scores were also simplified. As a result, the risk for
renal death was divided from the previous 100 ranges to
only 9 ranges, making this system much easier to use to
predict the prognosis. Also with this classification, higher
scores were assigned to laboratory test data-based sever-
ity as compared to the histological classification, indicat-
ing that this classification placed greater emphasis on the
laboratory abnormalities. Hematuria was also scored as a
risk factor, but it is noteworthy that probably because
macroscopic hematuria was found to be associated with a
good prognosis, in terms of the urinary red blood cell
count, mild hematuria (1-29/high-power field [HPF]) was
associated with a poorer prognosis than severe hematuria
(30/HPF or higher) (mild vs. severe hematuria: incidence
of renal death: 18.2 vs. 12.3%, odds ratio: 2.83 vs. 1.86).
To validate this severity classification, a validation study
was conducted in a cohort of 633 Caucasians in Norway,
with an follow-up period extended to 20 years.
１４
In that
study, the results of the multivariate analysis revealed ap-
proximately similar results in terms of the influence of
various factors, except for gender. The number of sever-
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Figure　1　Final decision tree model.
The final tree has branch points that permit patient stratification into seven risk groups. The risk of sub-
stantial deterioration in renal function: comparison between risk groups. 
Based on reference 15 Nephrol Dial Transplant 2009.
ity levels was reduced from the previous 9 to 5 on the ba-
sis of the cumulative renal death rate (Table 4c), and the
new grades of cumulative renal death rate yielded reason-
able results (Group A: 3.9%/20 years; Group B: 14.0%/
17.5 years; Group C: 42.3%/17.5 years; Group D: 60.9%/
15 years, E: 87.7%/10 years) . Furthermore, using the
data of the 790 cases aged 13 years or over with pre-
served renal function (eGFR60 mL/min/1.73 m2) in the
aforementioned cohort from 97 facilities in Japan, Goto
et al. prepared a decision tree model (Figure 1).１５ This
decision tree was confined to cases with a favorable
eGFR. For this reason, the laboratory test data-based se-
verity classification adopted five factors, including uri-
nary protein excretion (a major factor, known as the
strongest prognostic factor), mild hematuria, Alb, serum
total protein and diastolic blood pressure, while exclud-
ing renal function parameters. With this classification,
the severity was finally divided into 4 levels (minimal,
low, high and ultrahigh). Histological classification was
one of the minor factors in this severity classification,
which placed more emphasis on the laboratory test data-
based severity.
Conclusion
In this article, we provide an explanation about the labo-
ratory test data-based severity classifications proposed
until date. In recent years, risk factors (e.g., urinary pro-
tein excretion, hematuria, gradient of eGFR) taking into
account the efficacy of initial treatment during the first
year after diagnosis have also been reported. However,
for selection of the appropriate treatment soon after renal
biopsy and for prediction of the prognosis, the severity
based on the laboratory test data at the time of renal bi-
opsy seems to be very important, perhaps equivalent to
the findings of renal biopsy. In Japan, the 3rd edition of
the IgA nephropathy management guideline, revised tak-
ing into consideration both of these aspects, has been
published recently. Now, a prospective multicenter study
involving more than 1,000 cases in Japan is currently un-
der way for reassessing the validity of this type of sever-
ity classification. The study is expected to provide further
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